Histiocytosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HST010 MIFTS: 53	Histiocytosis Categories: Cancer diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis ¹² ⁵⁴ ⁴³ ¹⁵ ⁷¹

Hand Schuller Christian Disease ¹²

Hand-Schüller-Christian Disease ⁷⁴

Histiocytosis, Langerhans-Cell ⁷¹

Chronic Histiocytosis X ¹²

Histiocytic Syndrome ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3405

MeSH ⁴³ D015614

NCIt ⁴⁹ C3106

SNOMED-CT ⁶⁷ 60657004 65396000

SNOMED-CT via HPO ⁶⁸ 15771004 18265008 203522001 more

UMLS ⁷¹ C0019618 C0019621 C0398597

Sources

Summaries for Histiocytosis

Disease Ontology : ¹² A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as hand schuller christian disease, is related to alk+ histiocytosis and malignant histiocytosis. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and lymph node, and related phenotypes are osteolysis and proptosis

Wikipedia : ⁷⁴ Hand-Schuller-Christian disease is associated with multifocal Langerhans cell... more...

Sources

Related Diseases for Histiocytosis

Diseases in the Histiocytosis family:

Malignant Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 984)

#	Related Disease	Score	Top Affiliating Genes
1	alk+ histiocytosis	34.3	CD207 CD1A
2	malignant histiocytosis	34.2	TNFRSF8 SERPINA3 CD1A
3	non-langerhans-cell histiocytosis	33.8	SERPINA3 CD207 CD1C CD1A CD163
4	juvenile xanthogranuloma	33.1	SERPINA3 S100B CD1A BRAF
5	erdheim-chester disease	32.9	SERPINA3 NRAS CD1C CD1A CCR6 BRAF
6	rosai-dorfman disease	32.7	STAB1 SLC29A3 S100B MAP2K1 CD163 BRAF
7	dendritic cell tumor	32.5	S100B PTPRC CD207 CD1A
8	langerhans cell sarcoma	32.5	TNFRSF8 CD207 CD1C CD1A
9	reticulohistiocytic granuloma	32.3	SERPINA3 CD207 CD1C CD1A CD163
10	langerhans cell histiocytosis	31.5	U2AF1 S100B PTPRC NRAS MAP2K1 ITGAX
11	histiocytic sarcoma	30.8	CD163 BRAF
12	seborrheic dermatitis	30.8	CD207 CD1C CD1A
13	marginal zone b-cell lymphoma	30.4	U2AF1 TNFRSF8 CCR6
14	meningioma, familial	30.3	SERPINA3 PECAM1 CD1C CD1A
15	histiocytoma	30.3	SERPINA3 PTPRC PECAM1 CD1A CD163
16	plasma cell neoplasm	30.3	TNFRSF8 SERPINA3 PTPRC
17	lethal midline granuloma	30.3	TNFRSF8 SERPINA3
18	hodgkin's lymphoma, lymphocytic-histiocytic predominance	30.2	TNFRSF8 PTPRC
19	sarcoidosis 1	30.2	SERPINA3 PTPRC IL1RN CCR6
20	polyclonal hypergammaglobulinemia	30.2	SLC29A3 SERPINA3 CD1C CD1A
21	malignant fibroxanthoma	30.1	TNFRSF8 SERPINA3 PTPRC
22	hairy cell leukemia	30.1	U2AF1 MAP2K1 ITGAX BRAF
23	granuloma annulare	30.1	CD1C CD1A CD163
24	rhinoscleroma	30.0	CD1C CD1A
25	fibrous histiocytoma	30.0	SERPINA3 S100B PECAM1 CD163
26	reticulosarcoma	30.0	TNFRSF8 SERPINA3 PTPRC
27	skin sarcoidosis	30.0	CD1C CD1A
28	lymph node disease	29.9	SERPINA3 PTPRC ITGAX CCR6
29	mycosis fungoides	29.9	TNFRSF8 CD1C CD1A CCR6
30	orbital cancer	29.9	CD1C CD1A
31	bone lymphoma	29.9	TNFRSF8 PTPRC
32	amelanotic melanoma	29.8	SERPINA3 S100B BRAF
33	interdigitating dendritic cell sarcoma	29.8	SERPINA3 CD1C CD1A
34	sarcoma	29.8	S100B PTPRC NRAS MAP2K1 BRAF ARAF
35	myeloma, multiple	29.8	U2AF1 TNFRSF8 PTPRC NRAS CCR6 BRAF
36	spongiotic dermatitis	29.8	CD1C CD1A CCR6
37	hodgkin's lymphoma, mixed cellularity	29.7	TNFRSF8 PTPRC
38	giant cell tumor	29.6	SERPINA3 S100B PTPRC
39	reticulum cell sarcoma	29.6	TNFRSF8 PTPRC
40	demyelinating disease	29.6	U2AF1 SERPINA3 PTPRC CCR6
41	chediak-higashi syndrome	29.5	SERPINA3 ITGAX CD207 CCR6
42	leiomyosarcoma	29.5	SERPINA3 S100B PTPRC PECAM1
43	central nervous system vasculitis	29.5	SERPINA3 IL1RN CCR6
44	adult xanthogranuloma	29.5	CD207 CD1C CD1A CD163
45	neurofibromatosis, type ii	29.2	SERPINA3 IL1RN CCR6
46	lung cancer susceptibility 3	29.2	U2AF1 SERPINA3 PECAM1 NRAS MAP2K1 CCR6
47	skin disease	29.1	TNFRSF8 SERPINA3 S100B CD1C CD1A CD163
48	mycobacterium tuberculosis 1	28.9	TNFRSF8 SERPINA3 PTPRC CD1C CD1A CCR6
49	dermatitis, atopic	28.9	TNFRSF8 SERPINA3 PTPRC ITGAX CCR6
50	spondyloarthropathy 1	28.9	IL1RN CD163 CCR6

Graphical network of the top 20 diseases related to Histiocytosis:

Sources

Symptoms & Phenotypes for Histiocytosis

Human phenotypes related to Histiocytosis:

³¹ (show all 7)

#	Description	HPO Frequency	HPO Source Accession
1	osteolysis ³¹	hallmark (90%)	HP:0002797
2	proptosis ³¹	hallmark (90%)	HP:0000520
3	diabetes insipidus ³¹	hallmark (90%)	HP:0000873
4	hepatomegaly ³¹	occasional (7.5%)	HP:0002240
5	papule ³¹	occasional (7.5%)	HP:0200034
6	pulmonary infiltrates ³¹	occasional (7.5%)	HP:0002113
7	lymphadenopathy ³¹	occasional (7.5%)	HP:0002716

MGI Mouse Phenotypes related to Histiocytosis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.77	ARAF BRAF CCR6 CD101 CD163 CD207
2	immune system	MP:0005387	9.44	ARAF BRAF CCR6 CD101 CD163 CD207

Sources

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Trametinib

Approved

Phase 4

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760 44516822

Protein Kinase Inhibitors

Phase 4

Cytarabine

Approved, Experimental, Investigational

Phase 2, Phase 3

147-94-4, 65-46-3

6253

Cladribine

Approved, Investigational

Phase 2, Phase 3

4291-63-8

20279

Mercaptopurine

Approved

Phase 2, Phase 3

50-44-2

667490

Vinblastine

Approved

Phase 2, Phase 3

865-21-4

13342 241903

Indomethacin

Approved, Investigational

Phase 2, Phase 3

53-86-1

3715

Vincristine

Approved, Investigational

Phase 2, Phase 3

2068-78-2, 57-22-7

5978

Zoledronic Acid

Approved

Phase 3

118072-93-8

68740

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3

50-18-0, 6055-19-2

2907

Busulfan

Approved, Investigational

Phase 2, Phase 3

55-98-1

2478

Antiviral Agents

Phase 2, Phase 3

Anti-Inflammatory Agents, Non-Steroidal

Phase 2, Phase 3

Analgesics, Non-Narcotic

Phase 2, Phase 3

Analgesics

Phase 2, Phase 3

2-chloro-3'-deoxyadenosine

Phase 2, Phase 3

Tocolytic Agents

Phase 2, Phase 3

Cyclooxygenase Inhibitors

Phase 2, Phase 3

Antimitotic Agents

Phase 2, Phase 3

Immunoglobulins, Intravenous

Phase 2, Phase 3

Rho(D) Immune Globulin

Phase 2, Phase 3

gamma-Globulins

Phase 2, Phase 3

Pharmaceutical Solutions

Phase 3

Anesthetics

Phase 3

Diphosphonates

Phase 3

Immunologic Factors

Phase 2, Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Alkylating Agents

Phase 2, Phase 3

Thymoglobulin

Phase 2, Phase 3

Levoleucovorin

Approved, Investigational

Phase 2

68538-85-2

Thioguanine

Approved

Phase 2

154-42-7

2723601

Etanercept

Approved, Investigational

Phase 2

185243-69-0

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

6741

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

5755

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Deferasirox

Approved, Investigational

Phase 2

201530-41-8

5493381

Iron

Approved, Experimental

Phase 2

7439-89-6, 15438-31-0

23925 27284

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Dimethyl sulfoxide

Approved, Vet_approved

Phase 2

67-68-5

679

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Olaparib

Approved

Phase 2

763113-22-0

23725625

Piperazine

Approved, Vet_approved

Phase 2

110-85-0

4837

Mebendazole

Approved, Vet_approved

Phase 2

31431-39-7

4030

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

11431660 5005498 5330286

Vemurafenib

Approved

Phase 2

918504-65-1

23252090 42611257

Denosumab

Approved

Phase 2

615258-40-7

Interventional clinical trials:

(show top 50) (show all 77)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)	Not yet recruiting	NCT03975829	Phase 4	dabrafenib;trametinib
2	H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis	Completed	NCT00488605	Phase 3	Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
3	LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis	Recruiting	NCT02205762	Phase 2, Phase 3	Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
4	Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)	Recruiting	NCT02670707	Phase 3	Cytarabine;Vinblastine/prednisone
5	Cobimetinib for BRAF-wild-type Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study	Recruiting	NCT04007848	Phase 3	Cobimetinib;Placebo oral tablet
6	Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma	Recruiting	NCT02739555	Phase 3	Acide Zoledronique MEDAC
7	In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders	Terminated	NCT00176826	Phase 2, Phase 3	Myeloablative conditioning regimen
8	The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells	Unknown status	NCT00084695	Phase 2	busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
9	Transplantation Using Umbilical Cord And Placental Blood	Unknown status	NCT00008164	Phase 2
10	Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)	Completed	NCT00588536	Phase 2	Methotrexate;6-Thioguanine;Leucovorin Calcium
11	Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis	Completed	NCT02389400	Phase 2	methotrexate
12	A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis	Completed	NCT01395004	Phase 2	GSK2110183
13	Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE)	Completed	NCT00048373	Phase 2	Etanercept
14	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
15	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism	Completed	NCT00176865	Phase 2	Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
16	A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease	Completed	NCT02281760	Phase 2	Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
17	HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies	Completed	NCT00145626	Phase 2	Chemotherapy and antibodies
18	CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease	Completed	NCT01049854	Phase 2	Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
19	Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation	Completed	NCT00055653	Phase 2	busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone
20	Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study	Recruiting	NCT04121819	Phase 2	Cytarabine
21	Thalidomide, Cyclophosphamide and Dexamethasone for Adult Patients With Recurrent/Refractory Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study	Recruiting	NCT04120519	Phase 2	thalidomide combined with dexamethasone and cyclophosphamide
22	Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders	Recruiting	NCT02425904	Phase 2	Clofarabine
23	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes	Recruiting	NCT03233204	Phase 2	Olaparib
24	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes	Recruiting	NCT03526250	Phase 2	Palbociclib
25	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations	Recruiting	NCT03220035	Phase 2	Vemurafenib
26	Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial	Recruiting	NCT03270020	Phase 2	Denosumab 70 MG/ML [Xgeva]
27	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions	Recruiting	NCT03213704	Phase 2	Larotrectinib;Larotrectinib Sulfate
28	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex	Recruiting	NCT03213665	Phase 2	Tazemetostat
29	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations	Recruiting	NCT03210714	Phase 2	Erdafitinib
30	NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients With Solid Tumors	Recruiting	NCT03213678	Phase 2	Samotolisib
31	The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation	Recruiting	NCT03585686	Phase 2	Vemurafenib;Cytarabine;2-chlorodeoxyadenosine
32	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	Recruiting	NCT03155620	Phase 2	Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
33	CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease	Recruiting	NCT02061800	Phase 1, Phase 2	Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
34	Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders	Recruiting	NCT02649972	Phase 2	Cobimetinib
35	An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations	Recruiting	NCT02124772	Phase 1, Phase 2	Trametinib;Dabrafenib
36	Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma	Recruiting	NCT01887522	Phase 2	Vinblastine + Nilotinib;Vinblastine
37	Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function	Active, not recruiting	NCT01473797	Phase 2	Cladribine
38	A Phase II Study of Lenalidomide for Adult Histiocyte Disorders	Active, not recruiting	NCT02523040	Phase 2	Lenalidomide
39	Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment	Active, not recruiting	NCT03096782	Phase 2	Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
40	A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.	Not yet recruiting	NCT04079179	Phase 2	Cobimetinib
41	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations	Not yet recruiting	NCT04195555	Phase 2	Ivosidenib
42	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations	Suspended	NCT03698994	Phase 2	Ulixertinib
43	Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis	Terminated	NCT00618540	Phase 2	fludarabine phosphate;melphalan
44	Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders	Terminated	NCT01050439	Phase 2
45	A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors	Terminated	NCT02012231	Phase 1, Phase 2	PLX8394
46	Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis	Withdrawn	NCT01796405	Phase 2	Clofarabine
47	PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA	Unknown status	NCT01884922	Phase 1	Nilotinib;Vinblastine
48	A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy	Completed	NCT00890747	Phase 1	sunitinib malate
49	Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies	Completed	NCT01471067	Phase 1	Melphalan;Fludarabine;Mycophenolate mofetil;Tacrolimus;Rituximab;ATG;Busulfan;Clofarabine
50	Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors	Active, not recruiting	NCT01677741	Phase 1	Dabrafenib

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Etoposide

etoposide phosphate

Thalidomide

Vinblastine

Vinblastine Sulfate

Cochrane evidence based reviews: histiocytosis

Sources

Genetic Tests for Histiocytosis

Sources

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

⁴⁰

Bone, Lung, Lymph Node, Skin, Thyroid, T Cells, Liver

Sources

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 8741)

#	Title	Authors	PMID	Year
1	[Eosinophilic granuloma of the temporal bone. Case report and literature review]. ⁵⁴ ⁶¹	Hellmann M...Sudhoff H	12717600	2003
2	Oral submucosal dendrocytes: factor XIIIa+ and CD34+ dendritic cell populations in normal tissue and fibrovascular lesions. ⁵⁴ ⁶¹	Regezi JA...Headington JT	1282135	1992
3	Bone marrow imprints of crystal-storing histiocytosis. ⁶¹	Kilic I...Pambuccian SE	31833659	2020
4	Altered cerebral perfusion in children with Langerhans cell histiocytosis after chemotherapy. ⁶¹	Han M...Yeom KW	31802628	2020
5	Comment on: FDG PET-CT in pediatric Langerhans cell histiocytosis: Can all birds be killed with just one stone? ⁶¹	Buhtoiarov IN	32037736	2020
6	Erdheim-Chester disease: expanding the spectrum of cutaneous manifestations. ⁶¹	Kobic A...Mayo Clinic Histiocytosis Working Group	31120137	2020
7	Radiation Therapy for Benign Disease: Arteriovenous Malformations, Desmoid Tumor, Dupuytren Contracture, Graves Ophthalmopathy, Gynecomastia, Heterotopic Ossification, Histiocytosis. ⁶¹	Eng TY...Jane Sudmeier L	31739945	2020
8	Management of Hemophagocytic Lympho-Histiocytosis in Critically Ill Patients. ⁶¹	Lemiale V...Mariotte E	30384814	2020
9	Multiply relapsed mixed histiocytosis in an adult responding to clofarabine after failure of cladribine. ⁶¹	Othman J...Khoo TL	31483174	2020
10	Langerhans Cell Histiocytosis with Multiple Fluid-fluid Levels in the Parietal Bone. ⁶¹	Matsushita K...Miki Y	30828044	2020
11	High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis. ⁶¹	Ismail MB...Valentin H	31629106	2020
12	[Reaserch Advance on Langerhans Cell Histiocytosis Review]. ⁶¹	Fan ZQ...Bai H	32027303	2020
13	Adult vulvar Langerhans cell histiocytosis: a rare presentation. ⁶¹	Sousa C...Rocha N	31605379	2020
14	Sonographic features of Rosai-Dorfman disease in the breast: A case report. ⁶¹	Shin GW...Park H	31638720	2020
15	Lung Involvement in Destombes-Rosai-Dorfman Disease: Clinical and Radiological Features and Response to the MEK Inhibitor Cobimetinib. ⁶¹	Moyon Q...Cohen Aubart F	31669429	2020
16	Crystal-storing histiocytosis leading to the identification of IgG-kappa secreting lymphoplasmacytic lymphoma with crystalline nephropathy. ⁶¹	Reeders J...Lynnhtun K	31883675	2020
17	[Langerhans cell histiocytosis revealed by a temporomandibular joint disorder: Report of a case and review of the craniofacial expressions]. ⁶¹	Desbarats C...Trost O	31474430	2020
18	Aggressive surgical management of recurrent intracranial juvenile xanthogranuloma: case report and review of the literature. ⁶¹	AlQazlan S...Elwatidy S	31385088	2020
19	Reticulohistiocytoses: a revision of the full spectrum. ⁶¹	Bonometti A...Associazione Italiana Ricerca Istiocitosi ONLUS	31955466	2020
20	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. ⁶¹	Goyal G...Mayo Clinic Histiocytosis Working Group	31004029	2020
21	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. ⁶¹	Lim KPH...Allen CE	31899802	2020
22	Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. ⁶¹	Garces S...Medeiros LJ	31896812	2020
23	Mammary Extranodal Rosai-Dorfman Disease With and Without Associated Axillary Lymphadenopathy: Insights for Practitioners of Breast Pathology. ⁶¹	Shetty S...Sturgis CD	31992097	2020
24	Indeterminate cell histiocytosis in a patient with systemic lupus erythematosus and antiphospholipid antibody syndrome: an unusual association. ⁶¹	Akdogan N...Karaduman A	31789127	2020
25	Purpuric nail striae as the initial manifestation in multisystem Langerhans cell histiocytosis. ⁶¹	Prayogo RL...Arisanty R	31697424	2020
26	Spectrum of 18F-FDG Uptake in Bilateral Lung Parenchymal Diseases on PET/CT. ⁶¹	Prabhu M...Kumar R	31524673	2020
27	Diffuse Cystic Lung Diseases. ⁶¹	Obaidat B...Gupta N	31615921	2020
28	Empirical treatment of massive lymphadenopathy in a child with mixed type histiocytosis in Kenya. ⁶¹	Muma S...Halestrap P	31908285	2020
29	Response to trametinib of histiocytosis with an activating PTPN11 mutation. ⁶¹	Farnault L...Emile JF	31393194	2020
30	Spinal epidural involvement in adult Langerhans cell histiocytosis (LCH): A case report. ⁶¹	Lim CS...Cho JH	32011480	2020
31	MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. ⁶¹	Liu H...Borchers M	31961828	2020
32	Cyclin D1 and BRAF V600E Immunohistochemical Staining in Pulmonary Langerhans Cell Histiocytosis. ⁶¹	Pors J...Churg A	31965621	2020
33	Teaching NeuroImages: CNS pituitary-hypothalamic Langerhans cell histiocytosis in an adult. ⁶¹	Yeaney GA...Isada C	31932512	2020
34	Case of progression to multisystem Langerhans cell histiocytosis with polyostotic and cutaneous involvement from recurrent single-system monostotic Langerhans cell histiocytosis. ⁶¹	Yanagihara S...Kawada A	31677174	2020
35	Langerhans Cell Histiocytosis in an Adult: A Discussion of Epidemiology and Treatment Options. ⁶¹	El-Arab KK...Wang HT	31634312	2020
36	Solitary Bone Langerhans Cell Histiocytosis Demonstrated on Multimodality Imaging in an Adult. ⁶¹	Zhao Y...Su M	31789916	2020
37	Circulating cell-free BRAFV600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. ⁶¹	Cui L...Zhang R	31919077	2020
38	Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. ⁶¹	Kudo K...Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology	31758416	2020
39	The coming of age of Langerhans cell histiocytosis. ⁶¹	Allen CE...van Halteren A	31831887	2020
40	Acquired Von Willebrand Syndrome Secondary to Langerhans Cell Histiocytosis. ⁶¹	Radhakrishnan N...Dass J	31900848	2020
41	FDG PET-CT in pediatric Langerhans cell histiocytosis. ⁶¹	Jessop S...Howman-Giles R	31599488	2020
42	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. ⁶¹	Nelson CA...Mostaghimi A	31940000	2020
43	Rosai-Dorfman disease manifesting as epibulbar and orbital tumor: A case report and literature review. ⁶¹	Huang Q...He W	31914099	2020
44	Cytological Diagnosis of Rosai-Dorfman Disease: A Study of Twelve Cases with Emphasis on Diagnostic Challenges. ⁶¹	Rajyalakshmi R...Beulah Priscilla M	31942098	2020
45	Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders. ⁶¹		31810984	2020
46	Post-scabietic nodules: Mimicker of infantile indeterminate cell histiocytosis and potential diagnostic pitfall. ⁶¹	Ruby KN...LeBlanc RE	31381175	2020
47	Craniocervical Rosai-Dorfman Disease Involving the Vertebral Artery: Case Report and Literature Review. ⁶¹	Baassiri W...Darwish H	31550540	2020
48	Neuroimaging features of CNS histiocytosis syndromes. ⁶¹	Wang Y...Parmar HA	31874337	2019
49	Cardiothoracic manifestations of Erdheim-Chester disease. ⁶¹	Das JP...Halpenny DF	31386554	2019
50	Head and Neck Sinus Histiocytosis with Massive Lymphadenopathy Radiology-Pathology Correlation. ⁶¹	Cracolici V...Ginat DT	29855802	2019

Sources

Genes for Histiocytosis

Genes related to Histiocytosis (0 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	SLC29A3	Solute Carrier Family 29 Member 3	Protein Coding	35.6	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
2	CD1A	CD1a Molecule	Protein Coding	26.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17378241 12717600
3	CD207	CD207 Molecule	Protein Coding	25.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17378241
4	SERPINA3	Serpin Family A Member 3	Protein Coding	19.96	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
5	CD101	CD101 Molecule	Protein Coding	18.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
6	S100B	S100 Calcium Binding Protein B	Protein Coding	17.53	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1282135
7	CD1C	CD1c Molecule	Protein Coding	16.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	15	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
9	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	14.7	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
10	STAB1	Stabilin 1	Protein Coding	14.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	17229202
11	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	14.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	13.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	13.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CD163	CD163 Molecule	Protein Coding	13.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	12.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	12.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	ITGAX	Integrin Subunit Alpha X	Protein Coding	12.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	12.73	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	12.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	12.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	IL17A	Interleukin 17A	Protein Coding	12.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CSF1R	Colony Stimulating Factor 1 Receptor	Protein Coding	12.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	CSF2	Colony Stimulating Factor 2	Protein Coding	12.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	TNF	Tumor Necrosis Factor	Protein Coding	12.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	12.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Histiocytosis

Sources

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Sources

Pathways for Histiocytosis

Pathways related to Histiocytosis according to GeneCards Suite gene sharing:

(show all 34)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁵ Show member pathways Immune System ⁶⁵ Neutrophil degranulation ⁶⁵	13.45	TNFRSF8 SERPINA3 S100B PTPRC PECAM1 NRAS
2	Cytokine Signaling in Immune system ⁶⁵ Show member pathways Signaling by Interleukins ⁶⁵	13.3	TNFRSF8 NRAS MAP2K1 ITGAX IL1RN BRAF
3	Beta-Adrenergic Signaling ⁶³ Show member pathways CDK5 Pathway ⁶³ Erythropoietin Pathway ⁶³ Insulin Receptor Pathway ⁶³	12.74	NRAS MAP2K1 ITGAX BRAF ARAF
4	Regulation of actin cytoskeleton ³⁶ ¹	12.55	NRAS MAP2K1 ITGAX BRAF ARAF
5	Development ERBB-family signaling ²² Show member pathways Development EGFR signaling pathway ²² EGF Pathway ⁶³ EGFR Signaling Pathway ⁶⁶ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.45	NRAS MAP2K1 BRAF ARAF
6	RANK Signaling in Osteoclasts ⁶³ Show member pathways Apoptosis and survival APRIL and BAFF signaling ²² APRIL Pathway ⁶³ BAFF in B-Cell Signaling ⁶³ RANK Pathway ⁶³ RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling Pathway ¹	12.36	NRAS MAP2K1 BRAF ARAF
7	B cell receptor signaling pathway (KEGG) ¹ Show member pathways B cell receptor signaling pathway ³⁶ B Cell Receptor Signaling Pathway ¹	12.35	PTPRC NRAS MAP2K1 BRAF
8	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.33	NRAS MAP2K1 ITGAX BRAF ARAF
9	CNTF Signaling ⁶³ Show member pathways FLT3 Signaling ⁶³ IL-3 Pathway ⁶³ Nur77-Induced AICD in Macrophage ⁶³ OSM Pathway ⁶³	12.27	NRAS MAP2K1 BRAF ARAF
10	Proteoglycans in cancer ³⁶	12.23	NRAS MAP2K1 BRAF ARAF
11	Paradoxical activation of RAF signaling by kinase inactive BRAF ⁶⁵ Show member pathways MAP2K and MAPK activation ⁶⁵ Signaling by high-kinase activity BRAF mutants ⁶⁵ Signaling by moderate kinase activity BRAF mutants ⁶⁵ Signaling by RAS mutants ⁶⁵	12.22	NRAS MAP2K1 BRAF ARAF
12	Long-term potentiation ³⁶ Show member pathways Common Pathways Underlying Drug Addiction ¹ Dopamine D1-Like Receptor Family Signaling Pathways ⁶⁴	12.12	NRAS MAP2K1 BRAF ARAF
13	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁵ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.12	NRAS MAP2K1 BRAF ARAF
14	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁴ Show member pathways Akt Signaling Pathway ⁶⁴	12.12	NRAS MAP2K1 ITGAX BRAF ARAF
15	mTOR Pathway ⁷⁰ Show member pathways Insulin Pathway ⁷⁰ TGF-beta Pathway ⁷⁰	12.09	NRAS MAP2K1 BRAF ARAF
16	NGF Pathway ⁶³ Show member pathways TRKA Signaling ⁶³	12.06	NRAS MAP2K1 BRAF ARAF
17	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12	NRAS MAP2K1 BRAF ARAF
18	Oncogenic MAPK signaling ⁶⁵ Show member pathways Signaling by BRAF and RAF fusions ⁶⁵	11.98	NRAS MAP2K1 BRAF ARAF
19	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁴	11.88	PTPRC ITGAX CD1C CD163
20	Serotonergic synapse ³⁶	11.86	NRAS MAP2K1 BRAF ARAF
21	MAP Kinase Signaling ⁴	11.83	NRAS MAP2K1 BRAF ARAF
22	TGF-beta Signaling Pathways ⁶⁴	11.82	MAP2K1 BRAF ARAF
23	Glioblastoma Multiforme ⁶³	11.8	NRAS MAP2K1 BRAF ARAF
24	Innate Lymphoid Cell Differentiation Pathways ⁶⁴	11.72	PTPRC CD101 CCR6
25	VEGF Pathway (Tocris) ⁶⁰ Show member pathways VEGF Pathway ⁷⁰	11.65	NRAS MAP2K1 BRAF ARAF
26	Bladder cancer ³⁶ ¹	11.57	NRAS MAP2K1 BRAF ARAF
27	B Cell Development Pathways ⁶⁴	11.51	TNFRSF8 PTPRC CD1C
28	Negative regulation of MAPK pathway ⁶⁵ Show member pathways RAF activation ⁶⁵	11.48	NRAS MAP2K1 BRAF ARAF
29	Semaphorin Signaling ⁶³	11.45	MAP2K1 BRAF ARAF
30	Long-term depression ³⁶	11.4	NRAS MAP2K1 BRAF ARAF
31	BDNF-TrkB Signaling ¹	11.22	NRAS MAP2K1 BRAF
32	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.19	NRAS MAP2K1 BRAF ARAF
33	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.04	NRAS MAP2K1 BRAF ARAF
34	Dendritic Cells Developmental Lineage Pathway ⁶⁴	10.97	PTPRC ITGAX CD207 CD1C CD1A CD163

Sources

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.86	TNFRSF8 STAB1 SLC29A3 PTPRC PECAM1 NRAS
2	external side of plasma membrane	GO:0009897	9.17	PTPRC PECAM1 ITGAX CD1C CD1A CD163

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	neutrophil degranulation	GO:0043312	9.77	SERPINA3 PTPRC PECAM1 NRAS ITGAX
2	MAPK cascade	GO:0000165	9.71	NRAS MAP2K1 BRAF ARAF
3	regulation of axon regeneration	GO:0048679	9.32	MAP2K1 BRAF
4	antigen processing and presentation, exogenous lipid antigen via MHC class Ib	GO:0048007	9.26	CD1C CD1A
5	antigen processing and presentation, endogenous lipid antigen via MHC class Ib	GO:0048006	9.16	CD1C CD1A
6	positive regulation of T cell mediated cytotoxicity	GO:0001916	9.13	PTPRC CD1C CD1A
7	DN2 thymocyte differentiation	GO:1904155	8.62	PTPRC CCR6

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.11	U2AF1 TNFRSF8 STAB1 SLC29A3 SERPINA3 S100B
2	lipopeptide binding	GO:0071723	9.26	CD1C CD1A
3	exogenous lipid antigen binding	GO:0030884	8.96	CD1C CD1A
4	endogenous lipid antigen binding	GO:0030883	8.62	CD1C CD1A

Sources

Sources for Histiocytosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Histiocytosis

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Classifications:

External Ids:

Summaries for Histiocytosis

Related Diseases for Histiocytosis

Diseases in the Histiocytosis family:

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Histiocytosis:

Symptoms & Phenotypes for Histiocytosis

Human phenotypes related to Histiocytosis:

MGI Mouse Phenotypes related to Histiocytosis:

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

Publications for Histiocytosis

Articles related to Histiocytosis:

Genes for Histiocytosis

Genes related to Histiocytosis (0 elite genes):

Variations for Histiocytosis

Expression for Histiocytosis

Pathways for Histiocytosis

Pathways related to Histiocytosis according to GeneCards Suite gene sharing:

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

Sources for Histiocytosis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :